TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05867420: A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors

Sponsor: AskGene Pharma, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 594 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05867420 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05867420 Rescue Dossier →